

# Prediction of severe acute exacerbation using changes in breathing pattern of COPD patients on home noninvasive ventilation

Sophie Blouet<sup>1</sup>  
Jasmine Sutter<sup>1</sup>  
Emeline Fresnel<sup>2</sup>  
Adrien Kerfourn<sup>2</sup>  
Antoine Cuvelier<sup>1,3</sup>  
Maxime Patout<sup>1,3</sup>

<sup>1</sup>Department of Pulmonary, Thoracic Oncology and Intensive Respiratory Care, Rouen University Hospital, Rouen, France; <sup>2</sup>Kernel Biomedical, Rouen University Hospital, Bois-Guillaume, France; <sup>3</sup>Normandie Univ, UNIRouen, EA3830-GRHV, Institute for Research and Innovation in Biomedicine, Rouen, France

**Introduction:** Acute exacerbation of COPD (AECOPD) is associated with poor outcome. Noninvasive ventilation (NIV) is recommended to treat end-stage COPD. We hypothesized that changing breathing pattern of COPD patients on NIV could identify patients with severe AECOPD prior to admission.

**Methods:** This is a prospective monocentric study including all patients with COPD treated with long-term home NIV. Patients were divided in two groups: a stable group in which patients were admitted for the usual respiratory review and an exacerbation group in which patients were admitted for inpatient care of severe AECOPD. Data from the ventilator were downloaded and analyzed over the course of the 10 days that preceded the admission.

**Results:** A total of 62 patients were included: 41 (67%) in the stable group and 21 (33%) in the exacerbation group. Respiratory rate was higher in the exacerbation group than in the stable group over the 10 days preceding inclusion ( $18.2 \pm 0.5$  vs  $16.3 \pm 0.5$  breaths/min, respectively) ( $P=0.034$ ). For 2 consecutive days, a respiratory rate outside the interquartile limit of the respiratory rate calculated over the 4 preceding days was associated with an increased risk of severe AECOPD of 2.8 (95% CI: 1.4–5.5) ( $P<0.001$ ). This assessment had the sensitivity, specificity, positive predictive, and negative predictive values of 57.1, 80.5, 60.0, and 78.6% respectively. Over the 10 days' period, a standard deviation (SD) of the daily use of NIV  $>1.0845$  was associated with an increased risk of severe AECOPD of 4.0 (95% CI: 1.5–10.5) ( $P=0.001$ ). This assessment had the sensitivity, specificity, positive predictive, and negative predictive values of 81.0, 63.4, 53.1, and 86.7%, respectively.

**Conclusion:** Data from NIV can identify a change in breathing patterns that predicts severe AECOPD.

**Keywords:** noninvasive ventilation, acute exacerbation of COPD, breathing pattern

## Introduction

Acute exacerbations of COPD (AECOPD) are associated with a higher mortality and have a negative impact on the quality of life.<sup>1,2</sup> AECOPD-related hospitalizations have an important economic burden for the health care system. Their cost has been estimated to 3,090USD per patient per year and is the leading driver of overall costs (56.7%).<sup>3</sup> AECOPD-related hospitalizations are more frequent in patients with end-stage COPD.<sup>4</sup>

Patients with end-stage COPD benefit from the use of home noninvasive ventilation (NIV).<sup>5,6</sup> Murphy et al<sup>5</sup> have shown that NIV increases admission-free survival for AECOPD. In France and across Europe, COPD is one of the most common indications for home NIV.<sup>7</sup>

Correspondence: Maxime Patout  
Rouen University Hospital, Service de Pneumologie, Oncologie Thoracique et Soins Intensifs Respiratoires, CHU de Rouen – Hôpital Bois-Guillaume, 146 Avenue du Maréchal Juin, 76230 Bois-Guillaume, France  
Email maxime.patout@chu-rouen.fr

Modern ventilators have a built-in software that records the usage of NIV and respiratory parameters such as respiratory rate, expired tidal volume, spontaneous inspirations, leaks, and residual apneic events.<sup>8,9</sup> These data are reliable for the home monitoring of NIV.<sup>9–11</sup> Their use is recommended by expert consensus.<sup>11</sup> Borel et al<sup>12</sup> have shown that data from built-in software could predict the onset of an AECOPD. They have shown that change in respiratory rate and in the percentage of triggered breaths was associated with the onset of AECOPD.<sup>12</sup> Such identification may trigger early therapy and alleviate the need of hospitalization.<sup>13</sup> Ventilators are now equipped with tele-transmission features that may authorize tele-monitoring of these patients with advanced chronic respiratory failure. The European Respiratory Society advocates for more research in that field for COPD patients.<sup>13</sup>

Tele-monitoring is a promising tool for the management of COPD patients.<sup>14</sup> However, we still have a lack of positive results from randomized controlled trials.<sup>15–17</sup> In Chatwin et al,<sup>15</sup> the negative results may be explained by day-to-day normal variability of respiratory pattern in COPD patients. Therefore, some normal changes may have triggered a non-required response from the tele-monitoring team.<sup>15–17</sup>

Our hypothesis was that changes in breathing pattern recorded by the NIV built-in software would occur in patients prior to admission for AECOPD.

Our primary endpoint was to investigate the association between the change in respiratory rate and severe AECOPD. Our secondary endpoints were to assess if changes in daily compliance to NIV, leaks, tidal volume, residual respiratory events, or overnight breaks from NIV use had a predictive value for detecting severe AECOPD.

## Methods

We conducted a prospective observational monocentric case–control study approved by the local ethics committee for non-interventional research (Comité d’Ethique de la Recherche non-interventionnelle du CHU de Rouen) (E2016-79) and registered on [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT03018470). In accordance with French regulation, no written consent was required. Hence, only oral informed consent was obtained.

We included all patients admitted to Rouen University Hospital respiratory ward with a confirmed diagnosis of COPD and established on long-term NIV for >4 months regardless of the reason of their admission. Based on their reason of admission, we divided the patients into the following three groups: 1) stable group that included patients with stable COPD admitted for planned outpatient respiratory review and not presenting any feature for AECOPD,

2) severe AECOPD group that included patients hospitalized for AECOPD, and 3) moderate AECOPD group that included patients admitted for planned outpatient respiratory review but had clinical features of moderate AECOPD that did not require admission.

For each patient, we retrieved their medical records and reported their comorbidities and the results of their sleep polygraphy before NIV initiation, last echocardiogram, and last lung function test. For the stable group, we used the results of the outpatient stay during which they were included in the trial. For patients with severe AECOPD, arterial blood gas and NIV settings were retrieved from their last outpatient assessment during which they had clinical stability. For patients with severe AECOPD, we collected results from admission blood samples, bacteriological sample, chest X-ray, length of stay, and outcome. Onset of exacerbation was determined using a standardized structured clinical questionnaire.

For each patient, we retrieved the memory card of their NIV devices and made a copy to a secured computer. Patients who had a mean compliance of <4 h/night were secondarily excluded.

After discharge, we performed an analysis of the data copied from the NIV memory card. For each patient, a dedicated Windows®-based software, ResScan v5.6.0 (Resmed, Moissy-Cramaye, France) or DirectView v2.4.1 (Philips Respironics, Carquefou, France), was used to analyze data from the NIV. We collected the data for each of the 10 days preceding the admission. Collected data were as follows: respiratory rate (breaths/min), daily compliance (h/day), expired tidal volume (mL), unintentional leaks (L), residual respiratory events (events/h), and overnight interruption of NIV use (interruption/night).


We assessed four different methods to evaluate a change in breathing pattern. Method A was derived from Borel’s method:<sup>12</sup> quartiles of each parameter were calculated over a 5-day moving window, if the value on the following day was below the first quartile or above the third quartile, it was identified as an abnormal value that had to be confirmed on 2 consecutive days. Method B was adapted from method A but included only a 4-day moving window. For method C, we performed the following analysis: standard deviation (SD) was calculated for each 2 consecutive days, if the SD varied for >5% the following day, the value was identified as abnormal and had to be confirmed for 2 consecutive days. For method D, we calculated the SD over the 10 days period.

Normal distribution was assessed using the Shapiro–Wilk test. Results are expressed as number and percentages, mean and SD when normally distributed or medians, and

interquartile range (IQR) when not normally distributed. Comparisons were performed using the unpaired *t*-test for normally distributed continuous variables and a Mann–Whitney test for non-normally distributed continuous variables. Receiver-operator characteristic (ROC) analyses were used to identify predictors of admission for AECOPD. All tests were two-sided with type I error rate set at 0.05. The analyses were performed using GraphPad Prism 6 for Mac OS X (GraphPad Software, Inc., La Jolla, CA, USA) and IBM SPSS Statistics v20.0 (IBM Corporation, Armonk, NY, USA).

## Results

A total of 103 patients were included in the cohort, and 62 (60%) patients were included in the final analysis (Figure 1). Reasons for exclusions are shown in Figure 1. Patients' baseline characteristics are summarized in Table 1. All patients were ventilated using a spontaneous timed mode except three patients in the stable group who were ventilated using a volume-targeted pressure-assured mode ( $P=0.519$ ). Patients admitted for AECOPD were similar to those admitted for their routine assessment apart from: the



**Figure 1** Study flow chart.

**Abbreviation:** NIV, noninvasive ventilation.

**Table 1** Population characteristics (data reported as mean or median with SD or interquartile range where appropriate)

	Patients with severe AECOPD (n=21)	Stable patients (n=21)	P-value
Age (years)	69.8±1.7	66.5±1.4	0.174
Gender (male), n (%)	16 (76)	22 (54)	0.147
Comorbidities			
Hypertension, n (%)	16 (76)	27 (66)	0.586
Atrial fibrillation, n (%)	7 (33)	5 (12)	0.098
Ischemic heart disease, n (%)	3 (14)	6 (15)	0.731
Stroke, n (%)	1 (5)	9 (22)	0.731
Diabetes, n (%)	3 (14)	6 (15)	0.731
Sleep apnea syndrome, n (%)	8 (38)	14 (34)	0.976
LVEF (%) in stable state (n=43)	61.0±2.7	62.0±2.0	0.776
PAPs (mmHg) in stable state (n=39)	43.0±2.7	35.0±2.0	0.019
COPD			
Smoking history (pack-years)	40 (25–70)	40 (25–58)	0.891
Active smoker (yes), n (%)	4 (19)	9 (22)	0.949
Number of moderate AECOPD within the last 12 months	1 (0–2)	1 (0–1)	0.076
Number of severe AECOPD within the last 12 months	1 (0–2)	1 (0–1)	0.020
Days since last severe AECOPD	259 (81–895)	447 (87–969)	0.653
mMRC: from 0 to 4	3 (2–4)	3 (2–4)	0.863
COPD assessment test at admission	22 (16–23)	19 (07–23)	0.353
Lung function test at stable state			
FEV <sub>1</sub> (L) (n=58)	0.71 (0.36–1.01)	0.82 (0.49–1.14)	0.293
FEV <sub>1</sub> (% predicted)	29.6±3.0	37.1±3.2	0.131
FVC (L) (n=58)	1.77±0.18	1.83±0.12	0.822
FVC (% predicted)	57.7±5.5	62.5±4.8	0.538
FEV <sub>1</sub> /FVC	41.1±4.0	49.4±2.6	0.078
TLC (L)	7.27 (6.8–7.9)	6.88 (6.0–7.6)	0.276
TLC (% predicted)	128 (101–143)	123 (106–148)	0.681
6-Min walking test in stable state (distance in meters) (n=43)	166 (120–368)	261 (180–337)	0.118
ABG in spontaneous breathing in stable state (n=62)			
pH	7.38 (7.37–7.41)	7.39 (7.36–7.42)	0.648
PaCO <sub>2</sub> (kPa)	7.2±0.21	6.9±0.19	0.281
PaO <sub>2</sub> (kPa)	9.9±0.37	10.1±0.32	0.717
Bicarbonates (mmol/L)	31.22±0.78	29.78±0.65	0.1824
ABG after 1 h on NIV in stable state (n=59)			
pH	7.40±0.01	7.42±0.01	0.072
PaCO <sub>2</sub> (kPa)	6.9±0.25	6.1±0.17	0.007
PaO <sub>2</sub> (kPa)	11.1±0.49	11.3±0.38	0.776
Bicarbonates (mmol/L)	30.9 (28.0–33.2)	28.1 (25.2–30.4)	0.016
NIV settings			
Positive inspiratory pressure (cmH <sub>2</sub> O)	21 (19–25)	21 (19–25)	0.664
Positive expiratory pressure (cmH <sub>2</sub> O)	7 (6–8)	6 (6–9)	0.670
Backup rate (l/min)	14 (12–14)	12 (12–14)	0.384

**Abbreviations:** ABG, Arterial Blood Gas; AECOPD, acute exacerbation of COPD; NIV, noninvasive ventilation; SD, standard deviation.

number of admission in the year preceding inclusion: one (0–2) in the severe AECOPD vs one (0–1) in the stable group ( $P=0.021$ ), control of hypoventilation in stable state assessed by daytime PaCO<sub>2</sub> and bicarbonates following 1 h on NIV: 6.91±0.49 kPa and 30.9 (28.0–33.2) mmol/L in the severe AECOPD vs 6.06±0.17 kPa and 28.2 (25.3–30.5) mmol/L in the stable group ( $P=0.006$  and 0.016, respectively) and for the level systolic pulmonary arterial pressure for those who had an echocardiography (n=39): 43±3 mmHg in the severe AECOPD vs 35±2 mmHg in the stable group ( $P=0.019$ ).

Patients admitted for AECOPD had a median onset of their symptoms 2 (IQR; 1–3) days prior to admission. Vital signs, results from admission arterial blood gas, and venous blood samples are reported in Table 2. Patients admitted for AECOPD remained acidotic for a median period of 1 (IQR; 1–4) days. Their length of stay was 9 (IQR; 5–12) days. None of them required invasive ventilation or died.

Data from built-in software are reported in Table 3 and are represented over time in Figure 2. Patients with severe AECOPD had a significantly higher respiratory rate than

**Table 2** Vital observations, arterial blood gas, and venous sample at admission for patients with severe AECOPD (n=21)

	Mean or median with SD or interquartile range
Observations	
Systolic blood pressure (mmHg)	141.9±5.0
Diastolic blood pressure (mmHg)	78.7±3.5
Heart rate (bpm)	93.1±3.9
Temperature (°C)	37.1±0.1
Respiratory rate (breaths/min)	23.5±1.1
Dyspnea (mMRC: from 0 to 4)	4 (3–4)
Arterial blood gas at admission	
pH	7.34±0.02
PaCO <sub>2</sub> (kPa)	9.5±0.52
PaO <sub>2</sub> (kPa)	8.8 (7.8–10.8)
Bicarbonates (mmol/L)	37.1±1.4
Venous blood samples	
White cell counts (g/L)	9.4 (8.1–13.8)
Neutrophils (g/L)	7.5±0.61
Eosinophils (g/L)	0.08 (0.02–0.21)
C-reactive protein (mg/L)	25 (7.5–86.5)

**Abbreviations:** AECOPD, acute exacerbation of COPD; SD, standard deviation.

stable patients over the 10 days preceding inclusion (18.2±0.5 vs 16.3±0.5 breaths/min, respectively) ( $P=0.034$ ). Using linear regression, the only significant change over time was the respiratory rate in patients with severe AECOPD ( $y=-0.2168 \times X + 19.55$ ,  $P=0.049$ ). SD over 10 days was significantly higher for patients with severe AECOPD for respiratory rate and daily compliance when compared with the stable group (2.1 [0.8–2.6] vs 0.7 [0.4–1.2] breaths/min and 1.5 [1.0–2.4] vs 0.9 [0.7–1.3] h/day) ( $P=0.003$  vs 0.021, respectively).

Usefulness of data from built-in software to predict admission for severe AECOPD according to prespecified analysis methods are reported in Table 4 and Figure 3. Respiratory rate was the parameter that gave the more consistent results regardless of the analysis method. Variability in the daily use of NIV assessed by methods C and D was the best predictor for severe AECOPD.

## Discussion

We have shown that change in the breathing pattern analyzed with data provided by NIV built-in software could predict admission for AECOPD. An increased variability in respiratory rate prior to admission was consistently able to predict admission for AECOPD regardless of the method used whereas an increased variability in daily use was the strongest predictor.


Our results confirmed that respiratory rate was a good predictor to detect AECOPD. Borel et al also identified a change in the percentage of trigger breaths as a predictor for AECOPD. Such difference can be explained by the design of our respective study.<sup>12</sup> In Borel's study, data from NIV were collected during a long period of stable state which was used for the calculation of the quartiles. In our study, we performed all of our estimations using the data from the 10 days preceding admission. We chose this 10-day window based on the hypothesis that given the frailty of the study population, they were unlikely to exacerbate for more than 10 days prior to admission and based on technical limitations on the built-in software of ventilators used in our population. This difference could also be explained by the fact that we aimed to identify severe AECOPD whereas Borel et al<sup>12</sup> aimed to identify all exacerbations regardless of their severity.

Our results also differ from Borel's regarding the criteria that we identified as predictors of severe AECOPD. In his study, a change in the percentage of triggered breaths was associated with an increased risk of AECOPD. In our study, despite having a similar set back-up rate, patients with AECOPD trended to have a lower percentage of triggered breaths. This result has to be interpreted cautiously given the number of patients and the large interquartile of percentage of triggered breaths in this group (39%–90%). We hypothesize this trend to be explained by patient ventilator asynchrony that may be more frequent in exacerbating patients. In our cohort, variation in the daily use of NIV was able to predict

**Table 3** Comparison of mean and SD values over the 10 days prior to admission in the stable group and in the group with severe AECOPD

	Mean or median values over 10 days			SD over 10 days		
	Patients with severe AECOPD (n=21)	Stable patients (n=41)	P-value	Patients with severe AECOPD (n=21)	Stable patients (n=41)	P-value
Respiratory rate (breaths/min)	18.2±0.8	16.3±0.5	0.034	2.1 (0.8–2.6)	0.7 (0.4–1.2)	0.003
Daily use (h/day)	8.4±0.5	8.0±0.4	0.568	1.5 (1.0–2.4)	0.9 (0.7–1.3)	0.021
Overnight breaks/night	0.6 (0.0–1.0)	0.6 (0.1–1.7)	0.627	0.7 (0–1.2)	0.5 (0.3–0.9)	0.938
Leaks (L)	5.5 (0.1–30.6)	6.2 (0–13.5)	0.583	0.8 (0.0–8.3)	2.0 (0.0–5.8)	0.902
Tidal volume (mL)	559 (435–727)	546 (463–716)	0.839	48 (31–99)	38.1 (27–101)	0.533
Percentage of triggered breath	63 (34–90)	73.8 (21–85)	0.776	10.4±1.6	7.4±0.8	0.057
Residual respiratory events	0.4 (0.2–9.3)	0.8 (0.3–2.7)	0.772	0.5 (0.3–4.7)	0.5 (0.2–1.5)	0.807

**Abbreviations:** AECOPD, acute exacerbation of COPD; SD, standard deviation.



**Figure 2** Change in the 10 days preceding admission (A) change in respiratory rate, (B) change in daily compliance, (C) change in triggered breath, (D) change in tidal volume on NIV, (E) change in unintentional leaks, (F) change in residual events (mean value per day for each parameter).  
**Abbreviations:** AECOPD, acute exacerbation of COPD; NIV, noninvasive ventilation.

outcome unlike in Borel’s study where daily use was only trending toward statistical significance. Daily use of NIV was only able to predict AECOPD by measuring daily variability assessed by the SD over 10 days or every 2 days but for at least 6 consecutive days. Such variability can be

explained by the fact that some patients would use their NIV more during an AECOPD and that some others would not be able to tolerate it longer due to phlegm or cough. In our cohort, we have also shown that a change in residual apneic events detected by the built-in software could predict severe

**Table 4** Performance of parameters recorded by ventilator to predict severe AECOPD

	Area under the curve (95% CI)	P-value	Cutoff value	Sensitivity	Specificity	PPV	NPV	Relative risk (95% CI)	P-value
Respiratory rate									
Method A	0.675 (0.518–0.833)	0.025	2 days	57.1	87.8	70.6	0.8	3.3 (1.8–6.8)	<0.001
Method B	0.694 (0.550–0.838)	0.013	2 days	57.1	80.5	60.0	78.6	2.8 (1.4–5.5)	0.004
Method C	0.67 (0.523–0.816)	0.03	3 days	57.1	61.0	42.3	73.5	1.6 (0.8–3.3)	0.191
Method D	0.689 (0.538–0.840)	0.015	SD: 1.53	61.9	75.6	56.5	79.5	2.8 (1.3–5.6)	0.006
Daily use									
Method A	0.537 (0.392–0.682)	0.634							
Method B	0.605 (0.468–0.742)	0.178							
Method C	0.729 (0.59–0.867)	0.003	6 days	61.9	80.5	61.9	80.5	3.2 (1.6–6.4)	0.002
Method D	0.703 (0.565–0.841)	0.009	SD: 1.085	81.0	63.4	53.1	86.7	4.0 (1.5–10.5)	0.001
Percentage of triggered breath									
Method A	0.578 (0.419–0.737)	0.319							
Method B	0.629 (0.490–0.768)	0.099							
Method C	0.51 (0.361–0.66)	0.894							
Method D	0.58 (0.423–0.736)	0.308							
Tidal volume									
Method A	0.537 (0.392–0.682)	0.634							
Method B	0.663 (0.514–0.812)	0.037	2 days	66.7	56.1	43.8	76.7	1.9 (0.9–4.0)	0.112
Method C	0.646 (0.496–0.796)	0.062							
Method D	0.525 (0.380–0.670)	0.749							
Leaks									
Method A	0.505 (0.350–0.66)	0.953							
Method B	0.549 (0.400–0.699)	0.527							
Method C	0.551 (0.396–0.707)	0.513							
Method D	0.523 (0.368–0.679)	0.766							
Residual events									
Method A	0.671 (0.525–0.817)	0.029	3 days	47.6	82.9	58.8	75.6	2.4 (1.3–4.6)	0.016
Method B	0.623 (0.469–0.777)	0.115							
Method C	0.524 (0.374–0.675)	0.755							
Method D	0.531 (0.366–0.696)	0.693							
Overnight breaks									
Method A	0.574 (0.422–0.726)	0.345							
Method B	0.614 (0.466–0.763)	0.143							
Method C	0.517 (0.362–0.671)	0.829							
Method D	0.492 (0.337–0.648)	0.923							

**Abbreviations:** AECOPD, acute exacerbation of COPD; NPV, negative predictive value; PPV, positive predictive value; SD, standard deviation.

AECOPD that could be explained by the fact that 38% of our cohort of patients who had a severe AECOPD had concomitant obstructive sleep apnea. Rostral fluid distribution is known to increase apneic events. In patient with AECOPD, we hypothesize that acute hypoxemia induced an increase in the right ventricular pressure that leads to fluid retention. Indeed, our patients with severe AECOPD had stable higher pulmonary arterial pressure. As a result of their fluid retention and rostral redistribution, the number of apneic events may increase.

We had a significant number of patients for whom data from built-in software could not be retrieved. This can be explained by the fact that some of the memory cards were defective or missing. For others, data were not usable because of an incomplete copy of the data contained in the memory card in the computer used for the trial. As the first analyses

of the memory card were carried out 1 month after initiation of the study, we were not able to retrieve the complete data set secondarily for those with missing data. Finally, some patients did not attend to the hospital with their NIV or had insufficient use of their NIV prior to the admission.

We focused on identifying severe AECOPD in a population with severe chronic respiratory insufficiency. Identification of such an event is crucial as it could help trigger earlier treatment and avoid admission. In our cohort, patients stayed 9 (IQR; 5–12) days. Therefore, despite not using a questionnaire-based assessment of AECOPD<sup>18</sup> as Borel et al,<sup>12</sup> we are confident that our patients had severe AECOPD.

New ventilators now have built-in transmission unit that allows tele-monitoring, and this has been shown to be feasible in NIV patients.<sup>19</sup> Therefore, our results could be used for remote early identification of severe AECOPD that

may avoid hospitalization. Given the costs of hospitalization, such strategy would be likely to be cost-effective. One of the advantages of such an approach would be the fact that patients would not have to participate actively to their monitoring. This may prevent withdrawal from the tele-monitoring.<sup>20,21</sup> However, to be generalized, the methods used to detect AECOPD in our study would need to be based on automatic algorithm in order to alert health care provider. This would require interoperable platforms between manufacturers' software or homogeneity of the ventilators used in each

center's cohort of patients. Given the low sensitivity of the detection methods that we used, we suggest that changes in breathing pattern should trigger an alarm to the health care provider who would then make telephone contact with the patient to further evaluate symptoms suggesting the onset of an AECOPD. Such strategy would need clinical validation and economical validation.

Our study provides new data on the ability to predict admission for AECOPD. However, the sensitivity of all the methods used remains low. Two main reasons are likely to





Figure 3 (Continued)





**Figure 3** Receiving operator curves for the prediction of admission for AECOPD for each ventilator parameter according to methods A, B, C, and D.

explain this limit. First, the onset of an AECOPD is variable. This is highlighted by the IQR (1–3) of symptoms' onset in our patients admitted for AECOPD. Hence, if the detection method requires 2 days outside the normal values, it may not detect the change before the patient's admission. In contrast, using a detection method that assesses day-to-day variability may produce too many false positives. Second, very little is known about the normal variability of breathing pattern of patients on NIV. In this study, we only assessed individual variability over a 10-day period, but Borel et al<sup>12</sup> assessed normality over a more prolonged period as data were collected from inclusion to the onset of an AECOPD. Moreover, as NIV was mainly used by our patients while asleep, we think that variability in respiratory rate was minimal. However, we advocate for larger dataset to be collected in line with the recommendations of the European Respiratory Society that highlight the needs of research in the field of tele-monitoring.<sup>13</sup>

## Conclusion

We have shown that data from NIV can identify a change in breathing patterns that predicts severe AECOPD. The clinical impact of the identification of such change remains to be evaluated.

## Acknowledgment

The authors thank Miss Gill Arbane for her careful reading and correction of the article.

## Disclosure

Dr MP reports grants from B&D Electromedical, personal fees from ResMed, grants and nonfinancial support from Fisher & Paykel, nonfinancial support from MSD, nonfinancial support from Asten, and grants from ADIR Association, outside the submitted work. The other authors report no conflicts of interest in this work.

## References

1. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. *Chest*. 2003;124(2):459–467.
2. Miravittles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. *Thorax*. 2004;59(5):387–395.
3. Khakban A, Sin DD, Fitzgerald JM, et al. Ten-year trends in direct costs of COPD: a population-based study. *Chest*. 2015;148(3):640–646.
4. Jouneau S. Acute exacerbation of COPD: prediction, biology and becoming. *Rev Mal Respir*. 2006;23(5, pt 2):32–36.
5. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. *JAMA*. 2017;317(21):2177.
6. Köhnelein T, Windisch W, Köhler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. *Lancet Respir Med*. 2014;2(9):698–705.
7. Lloyd-Owen SJ, Donaldson GC, Ambrosino N, et al. Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. *Eur Respir J*. 2005;25(6):1025–1031.
8. Pasquina P, Adler D, Farr P, Bourqui P, Bridevaux PO, Janssens JP. What does built-in software of home ventilators tell us? An observational study of 150 patients on home ventilation. *Respiration*. 2012;83(4):293–299.

9. Georges M, Adler D, Contal O, et al. Reliability of apnea-hypopnea index measured by a home bi-level pressure support ventilator versus a polysomnographic assessment. *Respir Care*. 2015;60(7):1051–1056.
10. Contal O, Vignaux L, Combescure C, Pepin JL, Jolliet P, Janssens JP. Monitoring of noninvasive ventilation by built-in software of home bilevel ventilators: a bench study. *Chest*. 2012;141(2):469–476.
11. Janssens JP, Borel JC, Pépin JL; SomnoNIV Group. Nocturnal monitoring of home non-invasive ventilation: the contribution of simple tools such as pulse oximetry, capnography, built-in ventilator software and autonomic markers of sleep fragmentation. *Thorax*. 2011;66(5):438–445.
12. Borel J, Pelletier J, Taleux N, et al. Respiratory parameters recorded by built-in ventilator software: a new tool for the early detection of exacerbation in COPD patients treated with long-term non-invasive ventilation? *Rev Mal Respir*. 2015;32:A31.
13. Ambrosino N, Vitacca M, Dreher M, et al; ERS Tele-Monitoring of Ventilator-Dependent Patients Task Force. Tele-monitoring of ventilator-dependent patients: a European respiratory society statement. *Eur Respir J*. 2016;48(3):648–663.
14. Esteban C, Moraza J, Iriberrri M, et al. Outcomes of a telemonitoring-based program (telePOC) in frequently hospitalized COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2016;11:2919–2930.
15. Chatwin M, Hawkins G, Panicchia L, et al. Randomised crossover trial of telemonitoring in chronic respiratory patients (TeleCRAFT trial). *Thorax*. 2016;71(4):305–311.
16. Tuggey JM, Plant PK, Elliott MW. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis. *Thorax*. 2003;58(10):867–871.
17. Walker PP, Pompilio PP, Zanaboni P, et al. Telemonitoring in COPD: the CHROMED study, a randomized clinical trial. *Am J Respir Crit Care Med*. Epub 2018 March 20.
18. Leidy NK, Wilcox TK, Jones PW, et al; EXACT-PRO Study Group. Development of the EXAcerbations of chronic obstructive pulmonary disease tool (EXACT): a patient-reported outcome (PRO) measure. *Value Health*. 2010;13(8):965–975.
19. Kessler R, Casan-Clara P, Koehler D, et al. COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD. *Eur Respir J*. 2018;51(1):1701612.
20. Cruz J, Brooks D, Marques A. Home telemonitoring in COPD: a systematic review of methodologies and patients' adherence. *Int J Med Inform*. 2014;83(4):249–263.
21. Paré G, Jaana M, Sicotte C. Systematic review of home telemonitoring for chronic diseases: the evidence base. *J Am Med Inform Assoc*. 2007;14(3):269–277.

## International Journal of COPD

### Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

Dovepress

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.